Drug intelligence / Profile preview

GS87

Development stage: Preclinical
Modality: Small Molecules

Overview

GS87 is a **selective inhibitor of glycogen synthase kinase-3 (GSK3)**, with IC50 values of 415 nM for GSK3α and 521 nM for GSK3β. It has been reported to activate GSK3-dependent signaling components and induce differentiation in acute myeloid leukemia (AML) cell lines, and is being studied in the context of treatment research for non-promyelocytic AML. **GS87 is specifically noted as a research compound and is not a marketed pharmaceutical**. Its activity appears to be more prominent in cancer research than as an antiviral agent[1].

Other names: GS87GS-87GS 87

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on GS87.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS87.

Explore the full profile